ENTA
What one share of Enanta Pharmaceuticals holds
Pharmaceutical Preparations
We are a biotechnology company that uses our robust, chemistry-driven approach and drug discovery capabilities to discover and develop small molecule drugs for virology and immunology indications.
Enanta Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.41 |
|---|---|
| Profit | −$2.34 |
| Capex (buildings and equipment) | $0.06 |
| Free cash flow | −$1.36 |
| Cash and investments | $1.90 |
| Book value | $3.47 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2011 | $22.55 | $1.32 | $0.24 | $12.69 | — | −$117.90 |
| 2012 | $16.85 | $1.13 | $0.10 | $9.04 | — | — |
| 2013 | $3.27 | −$0.67 | $0.06 | $1.03 | — | $6.16 |
| 2014 | $2.49 | $1.79 | $0.05 | $1.00 | — | $7.99 |
| 2015 | $8.34 | $4.09 | $0.12 | $3.85 | — | $12.62 |
| 2016 | $4.59 | $1.13 | $0.25 | $1.62 | — | $14.18 |
| 2017 | $5.30 | $0.91 | $0.13 | $2.58 | — | $15.78 |
| 2018 | $10.01 | $3.48 | $0.14 | $1.27 | — | $20.30 |
| 2019 | $9.79 | $2.21 | $0.26 | $3.15 | — | $23.47 |
| 2020 | $6.14 | −$1.81 | $0.07 | $0.28 | — | $22.69 |
| 2021 | $4.81 | −$3.92 | $0.04 | −$3.51 | — | $19.74 |
| 2022 | $4.18 | −$5.91 | $0.10 | −$4.22 | — | $15.46 |
| 2023 | $3.78 | −$6.38 | $0.43 | −$5.35 | — | $10.29 |
| 2024 | $3.20 | −$5.48 | $0.85 | −$4.57 | — | $6.02 |
| 2025 | $3.06 | −$3.84 | $0.60 | −$1.51 | — | $3.03 |